New COX-2 Inhibitors / 대한내과학회지
Korean Journal of Medicine
;
: 250-256, 2016.
Article
in Korean
| WPRIM
| ID: wpr-20338
ABSTRACT
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain and inflammation. There are two kinds of NSAID classified according to the selectivity of COX-2 inhibition non-selective NSAIDs and cyclooxygenase (COX)-2 inhibitors. Non-selective NSAIDs have a high incidence of gastrointestinal and bleeding-associated adverse events, while COX-2 inhibitors are safer in terms of these events. However, COX-2 inhibitors are thought to cause increased cardiovascular events. The COX-2 inhibitors rofecoxib and valdecoxib were withdrawn from the market over safety concerns. Three COX-2 inhibitors are now available in South Korea after the recent approval of etoricoxib and polmacoxib for osteoarthritis patients. After reviewing the history of and recent studies about the safety of COX-2 inhibitors, physicians should find new uses for old drugs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Osteoarthritis
/
Anti-Inflammatory Agents, Non-Steroidal
/
Incidence
/
Cyclooxygenase Inhibitors
/
Prostaglandin-Endoperoxide Synthases
/
Cyclooxygenase 2 Inhibitors
/
Inflammation
/
Korea
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS